## 3 Results
\begin{table}
\begin{tabular}{p{113.8 pt} p{42.7 pt} p{42.7 pt} p{42.7 pt} p{42.7 pt} p{42.7 pt}} \hline \hline  & **1. D-SCZ (n = 42)** & **2. ND-SCZ (n = 76)** & **3. HCs (n = 60)** & **\(p\)** & **Significant Differences between Specific Groups** \\ \hline Age, years & 45.5 \(\pm\) 14.1 & 43.8 \(\pm\) 11.6 & 44.6 \(\pm\) 14.2 & 0.893 & - \\ \hline Sex, men (\%) & 31 (73.8) & 41 (53.9) & 39 (65.0) & 0.090 & - \\ \hline Education, higher (\%) & 6 (14.3) & 15 (19.7) & 8 (13.3) & 0.557 & - \\ \hline BMI, kg/m\({}^{2}\) & 29.3 \(\pm\) 5.3 & 28.4 \(\pm\) 6.0 & 26.6 \(\pm\) 4.3 & 0.019 & 1 \(>\) 3 \\ \hline WHR & 0.96 \(\pm\) 0.08 & 0.94 \(\pm\) 0.10 & 0.95 \(\pm\) 0.09 & 0.217 & - \\ \hline aMED & 2.2 \(\pm\) 0.8 & 2.4 \(\pm\) 1.1 & 3.1 \(\pm\) 1.3 & 0.015 & 1 \(<\) 3 \\ \hline FTND & 2.4 \(\pm\) 3.2 & 2.5 \(\pm\) 3.2 & 0.6 \(\pm\) 1.7 & \textless{}0.001 & 1 \(>\) 3, 2 \(>\) 3 \\ \hline Total PA, MET minutes/week & 2300.1 \(\pm\) 2612.7 & 2736.7 \(\pm\) 2184.1 & 3666.3 \(\pm\) 7093.7 & 0.021 & 1 \(<\) 3 \\ \hline RBANS–immediate memory & 33.6 \(\pm\) 9.7 & 38.5 \(\pm\) 10.0 & 46.2 \(\pm\) 6.1 & \textless{}0.001 & 1 \(<\) 2, 1 \(<\) 3, 2 \(<\) 3 \\ \hline RBANS–visuospatial/constructional & 34.6 \(\pm\) 4.5 & 31.7 \(\pm\) 7.4 & 37.3 \(\pm\) 2.8 & \textless{}0.001 & 1 \(<\) 3, 2 \(<\) 3 \\ \hline RBANS–language & 23.7 \(\pm\) 4.9 & 26.1 \(\pm\) 5.3 & 30.3 \(\pm\) 5.5 & \textless{}0.001 & 1 \(<\) 3, 2 \(<\) 3 \\ \hline RBANS–attention & 37.2 \(\pm\) 11.8 & 45.9 \(\pm\) 15.8 & 56.3 \(\pm\) 12.1 & \textless{}0.001 & 1 \(<\) 2, 1 \(<\) 3, 2 \(<\) 3 \\ \hline RBANS–delayed memory & 37.9 \(\pm\) 10.8 & 43.3 \(\pm\) 9.0 & 51.4 \(\pm\) 8.1 & \textless{}0.001 & 1 \(<\) 3, 2 \(<\) 3 \\ \hline RBANS–global cognition & 164.2 \(\pm\) 36.0 & 188.5 \(\pm\) 37.3 & 221.5 \(\pm\) 23.7 & \textless{}0.001 & 1 \(<\) 2, 1 \(<\) 3, 2 \(<\) 3 \\ \hline Illness duration, years & 20.7 \(\pm\) 12.8 & 18.9 \(\pm\) 12.7 & - & 0.437 & - \\ \hline CPZeq, mg/day & 683.1 \(\pm\) 382.9 & 529.2 \(\pm\) 329.8 & - & 0.025 & - \\ \hline CDS–depressive symptomatology & 1.8 \(\pm\) 3.1 & 1.5 \(\pm\) 2.8 & - & 0.633 & - \\ \hline PANSS–negative symptomatology & 17.6 \(\pm\) 5.3 & 8.9 \(\pm\) 4.7 & - & \textless{}0.001 & - \\ \hline SOFAS & 44.6 \(\pm\) 11.5 & 67.8 \(\pm\) 19.9 & - & \textless{}0.001 & - \\ \hline \hline \end{tabular} Data are reported as mean and SD or n (percentage of cases). Abbreviations: aMED, adherence to Mediterranean diet score; BMI, body mass index; CDS8, Calgary Depression Scale for Schizophrenia; CPZeq, chlorpromazine equivalent dosage; D-SCZ, individuals with deficit schizophrenia; FTND, Fagerstrom Test for Nicotine Dependence; HCs, healthy controls; ND-SCZ, individuals with nondeficit schizophrenia; PA, physical activity; PANSS, Positive and Negative Syndrome Scale; RBANS, Repeatable Battery for the Assessment of Neurophysiological Status; SOFAS, Social and Occupational Functioning Assessment Scale; WHR, waist-to-hip ratio.  
\end{table} 
Table 1: Sample characteristics. healthy controls. The differences in CRP levels between patients with ND-SCZ and healthy controls were not significant. Due to significant between-group differences in BMI, FTND score, aMED score, total physical activity and CPZeq, these variables were further added as covariates to the ANCOVA when testing for differences in specific metabolic parameters. The ANCOVA revealed a significant effect of group (D-SCZ vs. ND-SCZ vs. healthy controls) on the levels of CRP, but not on HOMA-IR or triglyceride and HDL levels (Table 3). The bivariate correlations of CRP levels with clinical characteristics are presented in Table 4 and Figure 1. Higher CRP levels were significantly correlated with greater severity of negative symptoms and lower RBANS scores of attention in patients with schizophrenia in adjusted and unadjusted analyses. In healthy controls, higher CRP levels were significantly associated with lower RBANS scores of immediate memory and global cognition.